Compile Data Set for Download or QSAR
Report error Found 126 Enz. Inhib. hit(s) with all data for entry = 2881
TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384029(US10280166, Compound 346)
Affinity DataIC50: 0.400nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384033(US10280166, Compound 372)
Affinity DataIC50: 0.600nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383939(US10280166, Compound 7)
Affinity DataIC50: 1nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383959(US10280166, Compound 25)
Affinity DataIC50: 1nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383956(US10280166, Compound 19)
Affinity DataIC50: 1nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384010(US10280166, Compound 277)
Affinity DataIC50: 1nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383918(US10280166, Compound 1)
Affinity DataIC50: 1nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383965(US10280166, Compound 55)
Affinity DataIC50: 1.80nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384020(US10280166, Compound 313)
Affinity DataIC50: 2nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383937(US10280166, Compound 2)
Affinity DataIC50: 2nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383963(US10280166, Compound 46)
Affinity DataIC50: 2nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383991(US10280166, Compound 184)
Affinity DataIC50: 2.30nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383946(US10280166, Compound 9)
Affinity DataIC50: 3nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384039(US10280166, Compound 433)
Affinity DataIC50: 3nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383972(US10280166, Compound 82)
Affinity DataIC50: 3.5nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383960(US10280166, Compound 28)
Affinity DataIC50: 4nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384032(US10280166, Compound 367)
Affinity DataIC50: 4.30nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383993(US10280166, Compound 202)
Affinity DataIC50: 4.70nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384028(US10280166, Compound 340)
Affinity DataIC50: 4.90nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384057(US10280166, Compound 1875)
Affinity DataIC50: 5nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384016(US10280166, Compound 298)
Affinity DataIC50: 5nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384007(US10280166, Compound 269)
Affinity DataIC50: 5.10nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384015(US10280166, Compound 295)
Affinity DataIC50: 5.10nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384011(US10280166, Compound 279)
Affinity DataIC50: 5.20nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383971(US10280166, Compound 81)
Affinity DataIC50: 5.80nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384041(US10280166, Compound 442)
Affinity DataIC50: 5.80nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384017(US10280166, Compound 304)
Affinity DataIC50: 6nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383967(US10280166, Compound 61)
Affinity DataIC50: 6nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384037(US10280166, Compound 421)
Affinity DataIC50: 6.10nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384026(US10280166, Compound 333)
Affinity DataIC50: 6.30nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384034(US10280166, Compound 373)
Affinity DataIC50: 6.40nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384006(US10280166, Compound 268)
Affinity DataIC50: 6.5nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384018(US10280166, Compound 306)
Affinity DataIC50: 6.70nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383973(US10280166, Compound 87)
Affinity DataIC50: 6.80nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384031(US10280166, Compound 358)
Affinity DataIC50: 6.90nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383992(US10280166, Compound 190)
Affinity DataIC50: 7.40nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383983(US10280166, Compound 148)
Affinity DataIC50: 8.10nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384009(US10280166, Compound 271)
Affinity DataIC50: 8.40nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384022(US10280166, Compound 320)
Affinity DataIC50: 8.80nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383958(US10280166, Compound 21)
Affinity DataIC50: 9.10nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384005(US10280166, Compound 265)
Affinity DataIC50: 9.40nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384012(US10280166, Compound 281)
Affinity DataIC50: 9.80nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384067(US10280166, Compound 1885)
Affinity DataIC50: 11nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383969(US10280166, Compound 71)
Affinity DataIC50: 11.1nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384044(US10280166, Compound 460)
Affinity DataIC50: 11.6nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383974(US10280166, Compound 90)
Affinity DataIC50: 12nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383970(US10280166, Compound 73)
Affinity DataIC50: 13nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM384030(US10280166, Compound 352)
Affinity DataIC50: 13.2nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383977(US10280166, Compound 109)
Affinity DataIC50: 13.7nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

TargetProto-oncogene Wnt-1(Human)
Samumed

US Patent
LigandPNGBDBM383982(US10280166, Compound 141)
Affinity DataIC50: 13.7nMAssay Description:Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) wit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2020
Entry Details
US Patent

Displayed 1 to 50 (of 126 total ) | Next | Last >>
Jump to: